Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares her recommendations for community physicians managing patients with polycythemia vera (PV), outlining the key considerations when selecting between the two main treatment options (oral hydroxyurea and interferon). Dr Masarova emphasizes the importance of patient preference and age when selecting a therapeutic strategy. Although oral hydroxyurea is a more convenient option, clinicians should consider interferon for eligible patients due to its ability to prolong event-free survival (EFS) and prevent progression and vascular events. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

0 Comments

Up next

Autoplay

#33: valsartan (Diovan) | Treating NSTEMI, STEMI, Heart Failure and Hypertension | Drug Cards Daily

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

Recommendations for physicians treating PV: selecting between hydroxyurea and interferon

Up next

Language